Vimarsana
Biggest News Aggregation in the World

Page 6 - Otonomy Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Otonomy Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Otonomy Inc Today - Breaking & Trending Today

Otonomy Announces Change in Stock Exchange Listing - Vimarsana News

Otonomy Announces Change in Stock Exchange Listing

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff...

Why ORIC Pharmaceuticals Shares Are Trading Higher By Around 46%; Here Are 27 Stocks Moving Premarket - Vimarsana News

Why ORIC Pharmaceuticals Shares Are Trading Higher By Around 46%; Here Are 27 Stocks Moving Premarket

Gainers Core Scientific, Inc. (NASDAQ:CORZ) shares rose 77.7% to $0.0906 in pre-market trading. Core Scientific shares dipped 75% on Wednes...

Syncona To Buy Applied Genetic Technologies, for Up to $73.5M - Vimarsana News

Syncona To Buy Applied Genetic Technologies, for Up to $73.5M

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

OTONOMY, INC. : Results of Operations and Financial Condition (form 8-K) - Vimarsana News

OTONOMY, INC. : Results of Operations and Financial Condition (form 8-K)

Item 2.02 Results of Operations and Financial Condition. Otonomy, Inc. reports that its estimated cash balance including cash and cash equivalents totaled $40.1 million as of September 30, 2022. The... | October 14, 2022

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial - Vimarsana News

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Arcutis Psoriasis Treatment Scores FDA App...